Aziyo Biologics, Inc. (AZYO)
Price:
1.49 USD
( + 0.03 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)

(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Abiomed, Inc.
VALUE SCORE:
0
2nd position
PROCEPT BioRobotics Corporation
VALUE SCORE:
9
The best
Viemed Healthcare, Inc.
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
DESCRIPTION
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
NEWS

Elutia to Present at the H.C. Wainwright 25th Annual Global Investment Conference
globenewswire.com
2023-09-08 08:30:00SILVER SPRING, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will take place in New York on Wednesday, September 13, 2023, at 2:30 pm ET.

Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures
globenewswire.com
2023-08-30 08:30:00Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket

Aziyo Biologics, Inc. (AZYO) Q2 2023 Earnings Call Transcript
seekingalpha.com
2023-08-20 12:41:05Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Matt Steinberg - FINN Partners Randy Mills - President and Chief Executive Officer Matthew Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Operator Good day, ladies and gentlemen. Welcome to the Aziyo Biologics' Second Quarter 2023 Financial Results Conference Call.

Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix Company
globenewswire.com
2023-08-14 16:05:00Negotiating multiple LOIs to divest Orthopedic business CanGaroo® RM 510(k) resubmission to the FDA remains on track SimpliDerm® quarterly net sales up 32% year-over-year Successful transfer of Cardiovascular product distribution to LeMaitre Vascular SILVER SPRING, Md., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the second quarter ended June 30, 2023.

Aziyo Biologics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
globenewswire.com
2023-07-31 16:05:00SILVER SPRING, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its second quarter 2023 financial results after market close on Monday, August 14, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.

Aziyo Biologics Announces Voluntary Recall of Viable Bone Matrix Products
globenewswire.com
2023-07-13 16:30:00SILVER SPRING, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced a voluntary recall of its viable bone matrix products, which are bone repair products made from human tissue that are used primarily in orthopedic and spinal procedures.

Aziyo Biologics, Inc. (AZYO) Q1 2023 Earnings Call Transcript
seekingalpha.com
2023-05-14 21:32:09Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations Randy Mills - Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Operator Good day, ladies and gentlemen. Welcome to the Aziyo Biologics First Quarter 2023 Financial Results Conference Call.

Aziyo Biologics to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
globenewswire.com
2023-05-03 16:05:00SILVER SPRING, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.

Aziyo Biologics, Inc. (AZYO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
zacks.com
2023-04-05 11:26:30Aziyo Biologics, Inc. (AZYO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Aziyo Biologics, Inc. (AZYO) Q4 2022 Earnings Call Transcript
seekingalpha.com
2023-03-22 18:12:04Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations, FINN Partners Randy Mills - Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Josh Jennings - TD Cowen & Company Operator Good day, ladies and gentlemen, and welcome to the Aziyo Biologics Fourth Quarter and Full Year 2022 Financial Results Call. At this time, all participants are in a listen-only mode.

ACER's Stock Down on Failure of Phase II Study, Cash Updates
zacks.com
2023-03-20 13:46:12ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.

Aziyo Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 22, 2023
globenewswire.com
2023-03-15 16:05:00SILVER SPRING, Md., March 15, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its fourth quarter and full year 2022 financial results after market close on Wednesday, March 22, 2023. Members of the Company's management team will host a conference call and webcast with accompanying slides starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.

Aziyo Biologics to Present at the Cowen 43rd Annual Health Care Conference
globenewswire.com
2023-02-27 08:15:00SILVER SPRING, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present at the Cowen 43rd Annual Health Care Conference. The presentation will take place at the Boston Marriott Copley Place on Monday, March 6, 2023, at 9:50 am ET.

Aziyo Biologics, Inc. (AZYO) Upgraded to Buy: Here's What You Should Know
zacks.com
2023-01-26 13:33:27Aziyo Biologics, Inc. (AZYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aziyo Biologics to Participate in Upcoming Investor Conferences
globenewswire.com
2022-11-21 16:05:00SILVER SPRING, Md., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced that management will be participating in the following investor conferences:

Aziyo Biologics, Inc. (AZYO) Q3 2022 Earnings Call Transcript
seekingalpha.com
2022-11-15 16:38:11Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Matt Steinberg - Fin Partners Randy Mills - CEO Matt Ferguson - CFO Conference Call Participants Josh Jennings - Cowen Simran Kaur - Piper Sandler David Rescott - Truist Securities Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Aziyo Biologics Third Quarter 2022 Earnings Conference Call.
No data to display

Elutia to Present at the H.C. Wainwright 25th Annual Global Investment Conference
globenewswire.com
2023-09-08 08:30:00SILVER SPRING, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will take place in New York on Wednesday, September 13, 2023, at 2:30 pm ET.

Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures
globenewswire.com
2023-08-30 08:30:00Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket

Aziyo Biologics, Inc. (AZYO) Q2 2023 Earnings Call Transcript
seekingalpha.com
2023-08-20 12:41:05Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Matt Steinberg - FINN Partners Randy Mills - President and Chief Executive Officer Matthew Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Operator Good day, ladies and gentlemen. Welcome to the Aziyo Biologics' Second Quarter 2023 Financial Results Conference Call.

Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix Company
globenewswire.com
2023-08-14 16:05:00Negotiating multiple LOIs to divest Orthopedic business CanGaroo® RM 510(k) resubmission to the FDA remains on track SimpliDerm® quarterly net sales up 32% year-over-year Successful transfer of Cardiovascular product distribution to LeMaitre Vascular SILVER SPRING, Md., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the second quarter ended June 30, 2023.

Aziyo Biologics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
globenewswire.com
2023-07-31 16:05:00SILVER SPRING, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its second quarter 2023 financial results after market close on Monday, August 14, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.

Aziyo Biologics Announces Voluntary Recall of Viable Bone Matrix Products
globenewswire.com
2023-07-13 16:30:00SILVER SPRING, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced a voluntary recall of its viable bone matrix products, which are bone repair products made from human tissue that are used primarily in orthopedic and spinal procedures.

Aziyo Biologics, Inc. (AZYO) Q1 2023 Earnings Call Transcript
seekingalpha.com
2023-05-14 21:32:09Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations Randy Mills - Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Operator Good day, ladies and gentlemen. Welcome to the Aziyo Biologics First Quarter 2023 Financial Results Conference Call.

Aziyo Biologics to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
globenewswire.com
2023-05-03 16:05:00SILVER SPRING, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.

Aziyo Biologics, Inc. (AZYO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
zacks.com
2023-04-05 11:26:30Aziyo Biologics, Inc. (AZYO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Aziyo Biologics, Inc. (AZYO) Q4 2022 Earnings Call Transcript
seekingalpha.com
2023-03-22 18:12:04Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations, FINN Partners Randy Mills - Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Josh Jennings - TD Cowen & Company Operator Good day, ladies and gentlemen, and welcome to the Aziyo Biologics Fourth Quarter and Full Year 2022 Financial Results Call. At this time, all participants are in a listen-only mode.

ACER's Stock Down on Failure of Phase II Study, Cash Updates
zacks.com
2023-03-20 13:46:12ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.

Aziyo Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 22, 2023
globenewswire.com
2023-03-15 16:05:00SILVER SPRING, Md., March 15, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its fourth quarter and full year 2022 financial results after market close on Wednesday, March 22, 2023. Members of the Company's management team will host a conference call and webcast with accompanying slides starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.

Aziyo Biologics to Present at the Cowen 43rd Annual Health Care Conference
globenewswire.com
2023-02-27 08:15:00SILVER SPRING, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present at the Cowen 43rd Annual Health Care Conference. The presentation will take place at the Boston Marriott Copley Place on Monday, March 6, 2023, at 9:50 am ET.

Aziyo Biologics, Inc. (AZYO) Upgraded to Buy: Here's What You Should Know
zacks.com
2023-01-26 13:33:27Aziyo Biologics, Inc. (AZYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aziyo Biologics to Participate in Upcoming Investor Conferences
globenewswire.com
2022-11-21 16:05:00SILVER SPRING, Md., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced that management will be participating in the following investor conferences:

Aziyo Biologics, Inc. (AZYO) Q3 2022 Earnings Call Transcript
seekingalpha.com
2022-11-15 16:38:11Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Matt Steinberg - Fin Partners Randy Mills - CEO Matt Ferguson - CFO Conference Call Participants Josh Jennings - Cowen Simran Kaur - Piper Sandler David Rescott - Truist Securities Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Aziyo Biologics Third Quarter 2022 Earnings Conference Call.